Heart Transplant for Advanced Heart Failure: A Review. (PubMed, JAMA) - Oct 13, 2026 - "Lifelong maintenance immunosuppression typically combines a calcineurin inhibitor, antiproliferative agents (typically mycophenolate mofetil or azathioprine) and corticosteroids, with selective use of induction therapy (intensive immunosuppression immediately after transplant). Acute rejection requiring treatment occurs in 20% to 25% of recipients within a year, and may be treated with high-dose corticosteroids, antithymocyte globulin, and B-cell-targeted therapies (such as rituximab or bortezomib)...Cardiac allograft vasculopathy is treated with statins, mechanistic target of rapamycin inhibitors (such as sirolimus or everolimus), and retransplant for severe cases...Heart transplant is the definitive therapy for carefully selected patients with advanced heart failure despite receiving optimal, guideline-directed therapy. After heart transplant, lifelong multidisciplinary care is necessary to manage immunosuppression, prevent and treat rejection and cardiac..."
Journal • Cardiovascular • Fibrosis • Heart Failure • Hypertension • Hypotension • Immunology • Infectious Disease • Mental Retardation • Oncology • Psychiatry • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Transplant Rejection • Transplantation • mTOR
|
|
Ashish S Shah; JoAnn Lindenfeld; Kaushik Amancherla; Kelly H Schlendorf; Ravi Shah
|